Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV

Viral Immunology

Volumn 22, Issue 6, 2009, Pages 445-449

  Malik, Zainab A ^a   Hailpern, Susan M ^b   Burk, Robert D ^b  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; COHORT ANALYSIS; EXPOSURE; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; SEROLOGY; SEROPREVALENCE; SPECIES; UTERINE CERVICITIS; VAGINITIS; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; CAPSID PROTEINS; DNA PROBES, HPV; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RISK; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SPECIES SPECIFICITY; UTERINE CERVICITIS; VAGINITIS; VIRAL INTERFERENCE; VIRUS LATENCY; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 71449126003     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0055     Document Type: Article

References (21)

1. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.
2. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, and Bierman R: Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996;174:679-689.
3. Burk RD, Kadish AS, Calderin S, and Romney SL: Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: correlation with biopsy results and Papanicolaou smear. Am J Obstet Gynecol 1986;154:982-989.
4. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA, and Landesman SH: Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996;23: 333-341.
5. Chan SY, Delius H, Halpern AL, and Bernard HU: Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy. J Virol 1995;69:3074-3083.
6. Combita AL, Bravo MM, Touze A, Orozco O, and Coursaget P: Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 2002;97:796-803.
7. Combita AL, Touze A, Bousarghin L, Christensen ND, and Coursaget P: Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002;76:6480-6486.
8. Gambhira R, Karanam B, Jagu S, et al.: A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007;81:13927-13931.
9. Garland SM, Hernandez-Avila M, Wheeler CM, et al., and the Females United to Unilaterally Reduce Endo/ Ectocervical Disease (FUTURE) I Investigators: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-1943. (Pubitemid 46740303)
10. Ho GY, Bierman R, Beardsley L, Chang CJ, and Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
11. Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, and Burk RD: Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002;186:737-742.
12. Ho GY, Studentsov YY, Bierman R, and Burk RD: Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004;13:110-116.
13. Joura EA, Leodolter S, Hernandez-Avila M, et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against highgrade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-1702.
14. Kirnbauer R, Booy F, Cheng N, Lowy DR, and Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-12184.
15. Kobayashi A, Greenblatt RM, Anastos K, et al.: Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004;64: 6766-6774.
16. Olsson SE, Villa LL, Costa RL, et al.: Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931-4939.
17. Passmore JA, Milner M, Denny L, et al.: Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia. Immunology 2006;119:507-514.
18. Studentsov YY, Schiffman M, Strickler HD, et al.: Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol 2002;40:1755-1760.
19. Villa LL, Costa RL, Petta CA, et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-278.
20. Viscidi RP, Schiffman M, Hildesheim A, et al.: Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a populationbased study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:324-327.
21. Woodman CB, Collins S, Winter H, et al.: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-1836.